Johannes Jacobus Oosthuizen Sells 15,000 Shares of Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) insider Johannes Jacobus Oosthuizen sold 15,000 shares of the company’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the sale, the insider owned 21,197 shares of the company’s stock, valued at approximately $2,583,278.39. The trade was a 41.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK traded up $2.17 during mid-day trading on Friday, reaching $121.92. The company had a trading volume of 13,080,359 shares, compared to its average volume of 14,211,604. The firm has a market cap of $302.61 billion, a price-to-earnings ratio of 16.75, a PEG ratio of 2.00 and a beta of 0.28. The business’s 50-day simple moving average is $106.23 and its 200 day simple moving average is $92.85. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $122.66. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.44 and a current ratio of 1.66.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 45.22%. Merck & Co., Inc.’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 46.70%.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds have recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $25,000. Darwin Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after acquiring an additional 216 shares during the period. Kilter Group LLC bought a new stake in Merck & Co., Inc. in the second quarter valued at approximately $27,000. Bare Financial Services Inc increased its position in Merck & Co., Inc. by 51.9% during the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after purchasing an additional 125 shares during the period. Finally, Barnes Dennig Private Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after buying an additional 266 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on MRK. Citigroup raised their target price on Merck & Co., Inc. from $115.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday. UBS Group lifted their target price on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price for the company in a report on Thursday, January 8th. Bank of America raised their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Wall Street Zen upgraded shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Hold” and an average target price of $119.53.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q4 results topped estimates (EPS and revenue) and management set FY‑2026 EPS guidance of $5.00–$5.15 while citing growth drivers such as Keytruda, Animal Health and new drug launches — a near-term earnings beat that supports upside. Earnings Beat
• Positive Sentiment: Guggenheim raised its price target from $122 to $140 and kept a Buy rating, giving analysts’ support to the rally and indicating ~15% further upside from recent levels. Guggenheim PT Raise
• Positive Sentiment: Other broker notes are bullish — Citigroup and Scotiabank published favorable outlooks/target increases highlighting execution and price appreciation potential. Citigroup Forecast Scotiabank Lift
• Neutral Sentiment: Zacks flags a “subdued” 2026 outlook driven by acquisition-related charges, which mutes the beat; but it still points to Keytruda, Animal Health and new launches as the primary growth levers — a mixed read on near-term margin/earnings progression. Zacks Analysis
• Negative Sentiment: Significant insider selling this week: CEO Robert M. Davis sold ~47,434 shares, CFO Caroline Litchfield ~41,997 shares, EVP Richard Deluca ~37,685 shares, CMO Chirfi Guindo ~20,000 and multiple other senior executives also trimmed positions — large, coordinated filings that may weigh on sentiment despite corporate explanations (e.g., diversification or tax/planned sales). SEC filings: CEO Form 4 CFO Form 4 EVP Form 4

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.